G9069 Small Cell Lung Cancer HCPCS Reimbursement

HCPCS Level II code G9069 identifies disease status for small cell lung cancer and is designated for use within a Medicare-approved demonstration project. The code captures whether the cancer is limited to small cell or combined small cell/non-small cell disease, or whether it is extensive at diagnosis, metastatic, locally recurrent, or progressive. Nationally, consistent classification of disease status supports program evaluation, clinical staging alignment, and targeted oncology reporting in demonstration settings.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical scope and intended service context, plus what to expect from payer coverage discussions and benchmarking materials when available. The publication outlines the policy and operational implications for sites of service such as hospital outpatient departments and oncology clinics participating in demonstration projects.

This report provides: a clear description of the code and its clinical meaning; the service types and typical settings where the code applies; the set of payers commonly evaluated in national analyses; and notes on missing input elements where data were not provided. Data not available in the input are explicitly identified, and readers will gain a practical reference for integrating G9069 into documentation and reporting workflows in the context of Medicare demonstration projects.

Billing Code Overview

HCPCS Level II code G9069 designates a disease status classification for small cell lung cancer. The description specifies use when the disease is limited to small cell and combined small cell/non-small cell or when it is extensive at diagnosis, metastatic, locally recurrent, or progressive, and is intended for use in a Medicare-approved demonstration project.

Service Type: Oncology — disease status reporting and classification

Typical Site of Service: Hospital outpatient departments, oncology clinics, or other cancer care settings participating in a Medicare demonstration project

Data not available in the input for payers, associated taxonomies, ICD-10 diagnoses, related codes, and service line.

Clinical Context

A 68-year-old patient with a long smoking history presents to a tertiary oncology clinic with progressive dyspnea, weight loss, and new neurologic symptoms. Imaging (CT chest and brain MRI) and bronchoscopic biopsy confirm small cell lung cancer with features of extensive-stage disease (metastatic to contralateral lung and brain). The patient is enrolled in a Medicare-approved demonstration project tracking disease status for small cell and combined small cell/non-small cell histologies. Clinical workflow: initial oncology consultation and staging, baseline labs and imaging, multidisciplinary tumor board review, initiation of systemic therapy (chemotherapy ± immunotherapy), periodic restaging with CT/PET and brain MRI, and documentation of disease status (response, progression, stable disease, or recurrence) at each follow-up visit to report using G9069 for demonstration-project case capture. Documentation includes pathology report, staging summary, imaging reports, treatment dates, performance status, and treatment intent (palliative). Typical site of service: hospital outpatient oncology clinic or comprehensive cancer center participating in the Medicare demonstration project.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier	Use when no specific modifier applies to the service being reported with `G9069`.

Taxonomy Code	Specialty	Notes
`208000000X`	Medical Oncology	Primary specialty managing small cell lung cancer systemic treatment and disease-status reporting.
`207RH0000X`	Hematology/Oncology	Combined specialty often involved in complex cancer care and demonstration project reporting.
`2084P0800X`	Radiation Oncology	Provides staging-related imaging interpretation and local therapy for metastatic sites; documents disease status changes.
`363L00000X`	Pulmonology	Performs diagnostic bronchoscopies and initial diagnosis; documents disease extent in thoracic evaluation.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C34.90`	Malignant neoplasm of unspecified part of unspecified bronchus or lung	General primary lung cancer code that may be used when site detail is limited while documenting small cell lung cancer status.
`C34.11`	Malignant neoplasm of upper lobe, right bronchus or lung	Site-specific lung primary commonly associated with small cell presentations and staging documentation.
`C34.12`	Malignant neoplasm of middle lobe, right bronchus or lung	Alternative site-specific primary used when tumor is located in the middle lobe and disease status is recorded.
`C77.9`	Secondary and unspecified malignant neoplasm of lymph node	Used when regional or distant lymph node metastasis is present and contributes to extensive-stage classification.
`C79.31`	Secondary malignant neoplasm of brain	Used when brain metastases are present and are part of the disease-status assessment for `G9069`.
`C78.7`	Secondary malignant neoplasm of liver and intrahepatic bile duct	Liver metastases are a common site of spread and affect staging and reporting of extensive disease.
`Z85.118`	Personal history of other malignant neoplasm of bronchus and lung	Used when documenting prior lung cancer history during longitudinal disease-status tracking in the demonstration project.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`31622`	Bronchoscopy, flexible or rigid, with bronchoalveolar lavage or washings, when performed	Diagnostic bronchoscopic sampling used to obtain tissue confirming small cell histology and establishing disease status prior to reporting `G9069`.
`88305`	Level IV pathology; surgical pathology, gross and microscopic examination	Pathology code for evaluation of biopsy specimens confirming small cell or combined histology used in disease-status documentation.
`71260`	CT scan, thorax; with contrast, high resolution (when performed for staging)	Cross-sectional imaging code commonly used for staging and restaging to document extent of disease for `G9069` reporting.
`78815`	Positron emission tomography (PET) combined with CT imaging, whole body	PET/CT used to assess metastatic disease burden and response over time in extensive-stage small cell lung cancer.
`70553`	MRI, brain, without and with contrast material	Brain MRI code used to detect or monitor brain metastases contributing to disease status assessments reported with `G9069`.
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	Typical follow-up visit level where disease status is documented and `G9069` reporting entries are generated.

OpenPayer

Summary & Overview

HCPCS G9069: Small Cell Lung Cancer Disease Status, Demonstration Project